Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease

Xinyi Zhou†, Nan Jin†, Fei Wang and Baoan Chen*

Abstract
It is well acknowledged that allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for numerous malignant blood diseases, which has also been applied to autoimmune diseases for more than a decade. Whereas graft-versus-host disease (GVHD) occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a common serious complication, seriously affecting the efficacy of transplantation. Mesenchymal stem cells (MSCs) derived from a wealth of sources can easily isolate and expand with low immunogenicity. MSCs also have paracrine and immune regulatory functions, leading to a broad application prospect in treatment and tissue engineering. This review focuses on immunoregulatory function of MSCs, factors affecting mesenchymal stem cells to exert immunosuppressive effects, clinical application of MSCs in GVHD and researches on MSC-derived extracellular vesicles (EVs). The latest research progress on MSC in related fields is reviewed as well. The relevant literature from PubMed databases is reviewed in this article.

Keywords: Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Graft-versus-host disease (GVHD), Mesenchymal stem cells (MSCs), Immunoregulatory function, MSC-derived extracellular vesicles (EVs)

Background
Allogeneic hematopoietic stem cell transplantation (allo-HSCT), as the most effective way to treat a variety of malignant blood diseases, has also been applied to improve the therapeutic effect of autoimmune diseases in recent years [1]. Though obvious progress has been made in the source of donor, regimen of condition, the type of HLA, prevention and treatment of graft-versus-host disease (GVHD), GVHD remains the most important complication after allo-HSCT, severely affecting the survival rate of transplant patients [2, 3].

According to diverse etiology and pathological principles and response to treatment, GVHD is clinically divided into acute and chronic. Acute GVHD (aGVHD) is characterized by the immune response of T helper cells 1 (Th1), while chronic GVHD is mainly related to the immunity of T helper cells 2 (Th2), showing the characteristics of autoimmune diseases [4]. aGVHD currently proceeds pathologically in 4 steps: (1) tissue damage caused by pretreatment, high-dose chemotherapy or radiation therapy; (2) activation of host antigen presenting cells (APC) and innate immune cells; (3) APC presents antigens, promotes the activation and proliferation of donor-derived T lymphocytes, generates and releases a large number of inflammatory factors, and then forms an inflammatory storm; (4) inflammatory factors recruit and induce effector cell proliferation, leading to target organ skin, liver, and intestine damage [5]. The severity of aGVHD is classified into 4 grades: Grade I (mild), II (moderate), III (severe), and IV (very severe). The clinical presentations of rash, digestive disorders and liver diseases can be referred to in the diagnosis of patients [6, 7]. In terms of the prevention of GVHD, the phosphatase inhibitors cyclosporine A (CsA) and tacrolimus play an immunosuppressive role by blocking the secretion of
Interleukin 2 (IL-2) and the expansion of T cells. Rapamycin is extensively used by expanding regulatory T cells (Treg) and inducing T cells to acquire-Treg (iTreg). These drugs can be utilized alone or in combination with glucocorticoids. Other preventive methods include using antithymic immunoglobulins, removal of T cells in vivo, and humanized anti-CD52 monoclonal antibodies to control GVHD and graft rejection [8].

At present, the overall effective rate of standard corticosteroid therapy is 50%, and the complete response rate of various immunosuppressive agents is about 30% [9]. Although aGVHD can be partially controlled by glucocorticoids and immunosuppressive agents, severe hormonal resistance, secondary infections, and weakened graft antitumor effects (GVL) still develop, and ultimately leads to treatment intolerance or tumor recurrence. Therefore, innovative biological treatment of aGVHD exerts a tremendous fascination on us.

Being one of the most common adult stem cells, mesenchymal stem cells (MSCs) are non-hematopoietic stem cells originally isolated from bone marrow [10]. It forms the bone marrow hematopoietic microenvironment and advance the proliferation and differentiation of hematopoietic stem cells significantly [11]. Possessing a morphology similar to fibroblasts, it can grow adhered to plastic culture flasks, self-renew and differentiate into osteoblasts, adipocytes, chondrocytes in vitro, expressing CD29, CD44, CD73, CD90, CD105 and CD166, yet not expressing hematopoietic stem cell markers such as CD11b, CD14, CD19, CD34, CD45 [12]. MSCs maintain unique immunological properties, which preserve immunosuppressive effects with low immunogenicity. Additionally, its low expression of HLA-I molecules, no expression of HLA-II molecules and CD40, CD80, CD86 and other costimulatory factors make MSCs more paramount in clinical application [13]. Numerous studies prove that MSCs plays an indispensable role in maintaining the regulation of peripheral immune tolerance, transplant tolerance, autoimmunity, tumor escape, and fetal maternal tolerance [14]. Researchers propose the concept of suicide gene in order to eradicate tumor cells without damaging normal cells. Hence, a promising carrier is required to deliver therapeutic gene to specific cancer site. By virtue of unique features namely low immunogenicity and good affinity with tumor tissue, MSCs is a potential candidate for the successful delivery [15–17].

In addition to tumor therapy, in recent years, MSCs have been clinically adopted to multiple diseases such as acute kidney-injury, myocardial infarction, autoimmune diseases and so on [18, 19]. Much of researches in the last two decades have revealed that co-transplantation with hematopoietic stem cells can reduce the incidence of GVHD and improve graft survival, as well as accelerate the reconstruction of hematopoietic and immune systems due to the immunological features of MSCs. Accordingly, MSCs has been used to prevent immune rejection after organ transplantation [20].

**Immunoregulatory function of MSCs**

Composed of a series of complex mechanisms, the immunoregulatory function of MSCs mainly achieved by contacting cells and the releasing immunoregulatory factors. There remains many unknowns and controversies in the current research.

MSCs interrelate with continuously cell turnover and replacement in body systems [21]. In terms of T cells, MSCs inhibit the proliferation and activation of T cells, and downregulate the secretion of inflammatory factors (such as IL-2, TNF-α, IFN-γ). MSCs are also involved in reducing the ratio of Th1/Th2, as well as the quantity of Th17 by the same means. Meanwhile, sums of data address that conventional T cells may transform to regulatory T cells (including CD4+CD25+FoxP3+ Treg, CD8+CD28− Treg and IL-10+Tr1) given the function of MSCs [22, 23]. Regarding CD4+CD25+FoxP3+ Treg, the crucial factor underlying dramatically modifying the mRNA of genes may be the regulation of MSCs. And Foxp3 complex has some unknown connection with these genes [24]. A considerable amount of literature reports that despite the major role stable Foxp3 expression plays in the phenotype and functional stability of Treg, inflammatory Treg may reduce Foxp3 expression and convert into effector T cells under certain inflammatory conditions. MSCs can impel the expression of Runt-related transcription factor 1 (RUNX1), RUNX3 and CBFβ complexes in Treg specific demethylation regions through cell-to-cell contact to enhance Foxp3 stability; Foxp3 complex post-transcriptional regulation can induce the transformation of traditional T cells to Treg and amplify Treg’s immunosuppressive function [24]. And the number and function of CD8+CD28-Treg may be enhanced by the stimulation of IL-10,FasL and apoptosis rate decrease resulted from the function of MSCs [25, 26]. In addition, MSCs engender HO-1 which induces and promotes the proliferation of IL-10+Tr1 [27]. As a member of IL-12 family, IL-35 (Interleukin-35) is concerned with maintaining immune tolerance by inducing the apoptosis of T cells and the proliferation of Treg. Guo noted that the quantity of Treg significantly increased after co-culture with MSCs which overexpress IL-35, whereas the percentage of CD4+T cells was lower than before [28]. Followed by over-expressing IL-35 in MSCs, MSCs can also specifically migrate to damaged liver tissues and prevent liver cells apoptosis by reducing the FasL expression of monocytes. Above all, IFN-γ secreted by liver monocytes is reduced.
through the regulation of JAK1-STAT1/STAT4 [29]. The inhibitory effect of MSCs on cytotoxic T lymphocyte (CTL) is performed mainly by inhibiting the proliferation of CTL. Such inhibitory effect can be observed in autologous and allogeneic effector cells [30, 31]. Furthermore, much of research found that MSCs suppress the lysis of CTL if added at the beginning of the mixed lymphocyte culture (MLC). However, if being added in the cytotoxic phase, the inhibition of the lysis could be eliminated. Additionally, some researchers suggested that the inhibitory effect of MSCs originates from soluble factors [32].

Further, with direct contact between cells and transforming the phenotype of natural killer (NK) cells, MSCs has also been proven highly effective in inhibiting the proliferation, cytotoxic effect and the secretion of various cytokines of NK cells. And indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (PGE2) might be the crucial factors of this function [33]. For B cells, MSCs can render the cell cycle stagnant in the G0/G1 phase and trigger the inhibition of B cells proliferation. According to transwell experiments, MSCs produce a slice of soluble factors which lead to the suppression of B cells. Also, the differentiation of B cells was inhibited by MSCs due to the impaired production of IgM, IgG, IgA. Moreover, chemotactic function of B cells can also be impacted by MSCs [34]. Recent studies indicated that MSCs can enlarge the proportion of regulatory B cells (Bregs), such as CD5+B cells, CD19+CD24highCD38high B cells, and other Bregs secreting IL-10 [35, 36]. Jiang also put forward that human MSCs, as the most efficient one among the antigen-presenting cells (APCs), can inhibit the transformation from monocyte into dendritic cells (DCs) [37]. Owing to the impact derived from MSCs on immune cells especially CD4+(±) CD25(±) regulatory T cells and DCs, Mirzaei et al. illustrated that MSCs had remarkable therapeutic effects on patients with multiple sclerosis and amyotrophic lateral sclerosis. Thus a conclusion can be drawn that the influences of MSCs are significant [18]. In the meantime, MSCs can inhibit the function of M1 macrophage cells, and induce the transformation of M1 macrophage cells to M2 macrophage cells. And through co-culture of MSCs and group 3 innate lymphoid cells (ILC3s) with IL-2, much of data addressed that the ILC3s proliferation and the production of IL-22 were upregulated. Afterwards, ILC3s induce the expression of ICAM-1 and VCAM-1 of MSCs mutually as well. Consequently, MSCs suppress the alloreactive T cells proliferation and induce the up-regulation of IL-22 via cellular contact and secretion of cytokines derived from MSCs [38] (Fig. 1). Furthermore, MSCs are correlated with the induction of transformation from macrophages (MOs) to a unique anti-inflammatory immunophenotype (MSC-educated MOs [MEMs]). MEMs impel the secretion of IL-6, which beneficially protects against graft host disease [39].

The paracrine effect of MSCs also plays a pivotal role in the realization of its immune regulatory function. Studies have shown that MSCs achieved direct immune regulation after the contact with effector T cells by releasing NO or Fas/FasL pathway, which induced apoptosis [32]. MSCs could directly secrete anti-inflammatory cytokines such as transforming growth factor (TGF-β), interleukin 6 (IL-6), interleukin 10 (IL-10), indolamine 2,3-dioxygenase (IDO), vascular endothelial growth factor (VEGF), intercellular adhesion molecule (ICAM), prostaglandin E2 (PGE2) and expression inhibitory co-stimulatory molecules such as programmed death ligand-1 (PD-L1) to realize the function of immunoregulation [40–42]. Further, it has been reported that Th1 and Th17 cells completed the repolarization process attributed to the increased expression of PD-L1 on MSCs, expanding in proportion of Th2 and Treg cells [43, 44]. Previous studies have emphasized that the immunosuppressive function of Tregs was considerably enhanced through co-culture of MSCs and Tregs. Moreover, the mechanism may originate from the up-regulation of IL-10 secretion leading to the increase of PD-1/87-H1 [45]. Interestingly, some researchers reported that a sum of indoleamine 2,3-dioxygenase (IDO) was produced after recipient phagocytes engulfing apoptotic MSCs, which played a crucial role in affecting immunosuppression [46].

The migration of MSCs to the site of injury or inflammation also plays a vital role as a necessary part of its therapeutic effect. It is widely acknowledged that MSCs express multiple chemokine receptors and growth factor receptors, such as CXCR1 [chemokine (C–X–C motif) receptor 1], CXCR2, CXCR4, CCR1 [chemokine (C–C motif) receptor 1], CCR2, PDGFR-α (platelet-derived growth factor receptors-alpha) [47]. With tissue or organs impaired, a large release of chemokines drive the MSCs to migrate to the damaged tissue and stimulate tissue repair. Ringe et al. reported that MSCs expressed chemokine receptors CXCR1, CXCR2 and CCR2, and the migration of MSCs was correlated with the stimulation of C-X-C motif chemokine ligand 8 (CXCL8) [48]. Furthermore, the impaired tissues could also secrete an ocean of chemokines, which motive the migration of MSCs [49].

**Factors affecting mesenchymal stem cells to exert immunosuppressive effects**

**Influence of soluble factors**

MSCs from diverse species exert influence on immune regulation differently. For human MSCs, IDO was indispensable in immunosuppression by degrading tryptophan and forming secondary metabolites in the microenvironment [50]. The expression of IDO gene in...
MSCs is linked to the IFN-γ-Janus kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) pathway. If infusing MSCs which over-express IDO gene, the clinical remission (CR) rate will be raised in GVHD patients. In addition to IDO, IFN-γ also takes a seat in effects [51]. IFN-γ generated from T cells suppress the proliferation of T cells, activating rat BM-MSCs by low concentrations of IFN-γ. While high concentrations of IFN-γ won’t take effect as mentioned above [52]. Moreover, transforming growth factor-β (TGF-β) and Prostaglandin E2 (PGE2) were further correlated to the function of MSCs. An army of results demonstrated that the secretion of PGE2 was mediated by the COX2/PGE2 pathway and stimulated the up-regulation of immunosuppression of MSCs. And the secretion of PGE2 was associated with the increase of PGES via TLR3 [53].

Normally, low levels of intercellular cell adhesion molecule (ICAM) are present on the surface of MSCs. After pretreatment of MSCs with appropriate concentration of proinflammatory cytokines such as IFN-γ, the production of ICAM such as galectin-1 and vascular cell adhesion molecule-1 (VCAM-1) up-regulate, resulting in contact-dependent effects. Specifically, the higher concentration of ICAM is, the greater its immunosuppressive effect will be, eventually boosting the suppressive effect of MSCs on T lymphocytes [54, 55]. Meanwhile, proinflammatory cytokines also induce MSCs to secrete chemokine ligand-9, CXC chemokine ligand 10 (CXCL-10), and CC chemokine ligand 2 (CCL2), etc., all of which are correlated with recruiting effector T cells. Once MSCs and effector T cells are in contact, the generated NO or Fas/FasL ligands activate the apoptosis of effector T cells [50, 56]. Mirzei et al. reported that CXCL10 significantly down-regulate angiogenesis and frequency of regulatory T cells in the lungs, and up-regulate the apoptosis of tumor cells and activated T cells trafficking to lungs. Therefore, the prospective of MSCs applied in treating melanoma lung metastasis patients is given [57]. Also, Yu suggested that the inhibition of microRNA let-7a expression affiliated with the 3’ UTR of mRNA of Fas and FasL could up-regulate the level of Fas/FasL, consequently enhancing the immunosuppressive efficiency of MSCs [58].

Fig. 1 Regulation of immune cells related with MSCs. MSCs interrelate with the regulation of immunoregulatory function of various cells. In terms of T cells, MSCs inhibit the proliferation and activation of T cell. Meanwhile, sums of data address that conventional T cells may transform to regulatory T cells (including CD4+CD25+FoxP3+Treg, CD8+CD28−Treg and IL-10+Tr1) given the function of MSCs. Further, with direct contact between cells and transforming the phenotype of natural killer (NK) cells, MSCs has also been proven highly effective in inhibiting the proliferation, cytotoxic effect and the secretion of various cytokines of NK cells. For B cells, MSCs can render the cell cycle stagnant in the G0/G1 phase and trigger the inhibition of B cells proliferation. Moreover, recent studies indicated that MSCs can enlarge the proportion of regulatory B cells (Bregs), such as CD5+ B cells, CD19+CD24highCD38high B cells, and other Bregs secreting IL-10. Jiang also put forward that human MSCs, as the most efficient one among the antigen-presenting cells (APCs), can inhibit the transformation from monocyte into dendritic cells (DCs). In the meantime, MSCs can inhibit the function of M1 macrophage cells, and induce the transformation of M1 macrophage cells to M2 macrophage cells. Also, MSCs are associated with the suppression of neutrophils.
Influence of oxygen concentration
The immunosuppressive effect of MSCs can be affected by the concentration of oxygen as well. A considerable amount of research has demonstrated that the extension of survival time, the decrease of oxidative stress, avoiding DNA damage and chromosomal aberration could result from MSCs cultured under hypoxia condition [59]. Moreover, under hypoxia conditions, MSCs tend to be stem-like, up-express typical surface markers and maintain multiple differentiation potential. The proliferation of MSCs and the secretion of indolamine 2,3-dioxygenase (IDO) are also promoted [52]. Further, mice that received MSCs cultured without oxygen or in low concentration of oxygen showed alleviated symptoms of GVHD and prolonged survival time [60]. Hypoxia inducible factor (HIF) pathway may be the trigger to the enhanced mechanism of MSCs in hypoxia, among which HIF-1α and HIF-2α are key molecules that have protective effects on MSCs. Chang et al. demonstrated that HIF-2α maintained MSCs cell viability and promoted cell proliferation related to the regulation of CyclinD1 (CCND1) and c-Myc (MYC) by the MAPK/ERK signaling pathway [61]. Similarly, Bingke et al. reported that HIF-1α was associated with the increasing of cell activity and the suppression of MSCs apoptosis under hypoxia conditions [62]. Liu et al. suggested that the differentiation and migratory ability of MSCs might be enhanced in low oxygen conditions through the Akt and NFκB pathways [63]. In addition, studies showed that hypoxic pretreated rat-derived BM-MSCs and human gum-derived MSCs up-regulated the expression of anti-inflammatory cytokines, given that the secretion of tumor necrosis factor (TNF) was inhibited and anti-inflammatory cytokine such as IL-10 was promoted [64, 65]. In consequence, the control of oxygen concentration plays a paramount role in the clinical application of MSCs.

Influence of distinct Toll-like receptors (TLR) ligands
Furthermore, an ocean of results illustrated that in endotoxemia models induced by lipopolysaccharide (LPS) pretreatment, the inflammation in various tissues such as lung and liver couldn’t be relieved after the infusion of BMSCs [66]. The potential mechanism lies in the association with Toll-like receptor (TLR) agonists as shown in Fig. 2. Sangiorgi et al. reported the immunosuppressive action of MSCs directly on T cells caused by LPS stimulating the TLR4 and increasing the gene expression of interleukin (IL)-1β and IL-6. By comparison, CpG oligodeoxynucleotides (CpG ODN) DSP30 also stimulated TLR9, up-regulating expression of transforming growth factor (TGF)-β1 and down-regulating tumor necrosis factor (TNF)-α expression. Subsequently, the proliferation and the immunosuppressive function of MSCs were promoted [67]. All this being said, it is well accepted that the damage to MSCs ability caused by LPS can be avoided through the application of CpG oligodeoxynucleotides (CpG ODN) DSP30. Further, when it comes to Toll-like receptor (TLR), it is necessary to mention the impact of pathogen associated molecular patterns (PAMP) on the function of MSCs. PAMPs induce the expression of cytokines and soluble factors by distinct signal pathways, and trigger an immune response [68]. PAMPs can be recognized by different TLRs on the MSCs, and send diverse signals depending on the pairing, for instance, TLR3/poly(I:C)
and TLR4/lipopolysaccharide (LPS). The potential of MSCs then could be altered [69–74].

Influence of the injection dose of MSCs
Generally, the therapeutic dose of MSC is $1 \sim 2 \times 10^6/\text{kg}$ and can be a maximum single dose of $1.2 \times 10^7/\text{kg}$ [50]. Rat BM-MSC exhibited a significant dose-dependent effect in vitro compared with rat AD-MSC, whereas the latter showed stronger immunosuppressive properties [75]. Interestingly, some reports suggested that the combination of MSCs and short-term mycophenolate mofetil (MMF) could obviously extend its survival time. However, there showed no statistical difference in survival at different doses of MSCs [76]. Despite there being no strong evidence to support the impact of MSCs dose on its immunosuppressive effect, the dose effect has exerted a tremendous fascination on many researchers.

Influence of immunosuppressant
During clinical practice, we routinely use immunosuppressive agents to prevent and alleviate GVHD. However, different types or doses of immunosuppressants may lead to completely different responses. Hajkova et al. indicated that the combination of MSCs and immunosuppressive agents not only promoted cell proliferation and Tregs function, but modulated the balance of distinct T-lymphocyte subsets [42]. Inoue et al. demonstrated the immunosuppressive effects of MSCs showed in vitro. Nevertheless, in a Lewis rats to ACI rats heart transplantation model, low-dose cyclosporine (CsA) was used continuously from 5 to 9 days and 0 to 3 days after surgery, the injection of donor rat BM-MSCs through the portal vein system and the tail vein was also applied, respectively. Consequently, rather than prolong the graft survival time, the therapy reversed the protective effect of CsA on the graft and shortened the survival time of the graft. This is possibly due to the disruption of pro-inflammatory cytokine environment caused by CsA, leading to an increased anti-donor response, which in turn prevents MSC activation [77]. In contrast, Hajkova et al. suggested that the combination of MSCs and CsA contributed to the alteration of macrophage phenotype (from M1 to M2), which also elevated the secretion of IL-10, in turn heightening the effect of MSCs-mediated therapy [78]. Besides, plenty of additional studies attempted to combine MSCs with mycophenolate mofetil (MMF), rapamycin and FK506 respectively, which displayed remarkable MSCs effects [79, 80]. Hence, MSCs combined with appropriate immunosuppressant can be far more effective with half the effort, which will also affect the prognosis of the patients.

Influence of temperature
Ian McClain-Caldwell et al. demonstrated that the heat shock protein, HSF1, could readily transfer into MSCs nucleus through the Cyclooxygenase2/Prostaglandin E2 (COX2/PGE2) pathway which potentially regulated the immunosuppressive function of MSCs at high temperatures [81]. Hyperthermia increases the efficacy of MSC-driven immune-suppression, yet detailed mechanisms need further exploring. The regulation of temperature could be a promising research orientation.

Clinical application of MSCs in GVHD
The first application of MSCs in GVHD was reported in 2004 and achieved a striking clinical response [82]. The clinical application of MSCs has been a new research hotspot for worldwide GVHD treatment ever since.

Application in acute graft-versus-host disease (aGVHD)
United States reported a case of MSC treating 75 children with B-D grade refractory aGVHD, in which the effective rate reached 61.3% after 28 days of MSCs infusion, significantly improving the overall survival after 100 days of MSCs infusion in patients [83]. In a meta-analysis of MSC treating refractory acute GVHD, the authors found that patients with pure skin involvement including grade I–II aGVHD showed better clinical efficacy, with clinical remission (CR) achieved after all courses. Furthermore, children responded better than that of adults. Instead, the treatment of severe intestines and liver aGVHD was not ideal [84]. In Turkey, 33 pediatric patients of steroid refractory acute anti-graft host disease were selected for MSC treatment with a drug dose of $1.18 \times 10^6$ MSCs/kg. A good complete response (CR) rate and 2-year overall survival (OS) rate were obtained after treatment. However, the transplant related mortality (TRM)in patients with PR/NR was 46.6% after 100 days of the first treatment, and some patients have adverse sequelae after all courses. Accordingly, though the therapeutic effect of MSC has been affirmed, its safety for pediatric patients needs further research [85]. Researchers made biologics (JR031) out of MSCs from healthy volunteers. According to I/II and subsequent II/III clinical studies, if enrolled patients (steroid-refractory aGVHD patients) are given intravenous injection at a concentration of $2 \times 10^6$ MSCs/kg once every 2 weeks for four consecutive weeks, the treatment can successfully alleviate clinical symptoms of patients and prolong survival with no observable adverse reactions [86]. Also, G M Dotoli et al. suggested that followed by MSCs treatment for steroid-refractory aGVHD, the overall survival in patients extended significantly and only 4.3% of the enrolled patients experienced the side effects such as nausea/vomiting and blurred vision.
Thus the effectiveness and safety of the MSCs treatment are proved [87]. Galleu et al. reported that only aGVHD patients with cytotoxicity against MSCs achieved better clinical response, while others showed no response to the treatment of MSCs. To obtain satisfactory remission, patients can be classified by capabilities of killing MSCs or direct infusion of apoptotic MSCs [46]. A single center case series of three patients, who underwent allogeneic hematopoietic cell transplantation and later developed steroid refractory GVHD, were treated with MSC infusions. Two patients achieved complete remission and one patient partial remission of skin and/or gastrointestinal aGVHD, which also confirmed that the application of MSC in treating severe steroid refractory aGVHD is feasible in clinical practice [88].

In a recent case report, a 15 years old boy diagnosed with a GVHD was infused at the concentration of $2 \times 10^6$ hMSCs/kg eight times in 4 weeks and continued MSCs administration once a week in the following 4 weeks. The Laboratory data was improved dramatically, and gastrointestinal symptoms were eased [89].

Besides, an ocean of data indicated that aGVHD could be alleviated with up-regulation of CXCL5 and anti-CCL24 antibody [90]. The mechanism is illustrated in the Fig. 3. Compared to the control group in sharp contrast, patients with the infusion of MSCs did not show remission during a large multicenter refractory GVHD phase III clinical trial in the United States [91]. Furthermore, the treatment with human-MSCs (hMSCs) by subconjunctival injection is effective in reducing corneal inflammation and squamous metaplasia in ocular GVHD (oGVHD), which makes local treatment with hMSCs a promising strategy for oGVHD [92]. However, a slice of studies held the view that instead of inducing immune tolerance in aGVHD, the treatment of MSCs was involved in breaking the vicious circle of GVH reaction due to the poor long term survival [93]. Based on the inconsistencies of clinical trial, further research on MSCs needs to be continued.

**Application in chronic graft-versus-host disease (cGVHD)**

Chronic anti-graft host disease is an intractable complication after allo-HSCT. The incidence of cGVHD is approximately 28–60% in patients who survive more than 100 days after allo-HSCT. At present, glucocorticoids and calcium antagonists remain the initial standard treatment for cGVHD, which is not satisfactory with significant related side effects. Some researchers demonstrated that MSCs applied in cGVHD could significantly alleviate the symptoms in distinct tissues such as liver, skin, oral mucosa and so on by increasing the population of CD5+ regulatory B cells (Bregs) and leading to the up-regulation of IL-10 [35]. Jurado et al. investigated that 14 cGVHD patients, of which 7 are moderate and 7 are severe, received the infusion of adipose tissue-derived MSCs (AT-MSCs) and the first-line treatments combined with cyclosporine and prednisone. Ten patients completed the trial within 56 weeks were able to stop hormones, 8 of whom achieved complete remission, 2 partial remissions. The clinical efficacy after the application of AT-MSCs showed significant superiority over the historical control group treated only by cyclosporine or tacrolimus and prednisone [94]. Zhang et al. enrolled a steroid refractory GVHD patient with nephrotic syndrome (NS) 10 months after allo-HSCT in 2017. Through MSCs therapy, the enrolled patient achieves complete remission.

**Fig. 3** The mechanism of combination of CXCL-5 and anti-CCL24. The potential mechanism lies in the synergy between CXCL5 and anti-CCL24 antibody (2FC). In vivo, 2FC could decrease not only transplanted Th 1 and Th 17 but also cytotoxic T lymphocytes and natural killer cells to increase immunosuppressive neutrophils without affecting human hematopoietic stem cell reconstitution. What’s more, it attenuates the secretion of FN-γ, IL-6, IL-17A, IL-8, macrophage inflammatory protein-1β, and macrophage chemoattractant protein-1. CXCL-5, Chemokine (C–X–C motif) ligand 5; Anti-CCL24, chemokine (C–C motif) ligand 24; Th, T helper cells; CTL, Cytotoxic T lymphocyte; NK cells, natural killer T cells; MIP-1β, macrophage inflammatory protein-1β; MCP-1, monocyte chemoattractant protein-1.
fungal infections [101]. However, some studies also suggest that mortality rates in terms of lung infection and tumor recurrence after the treatment of MSCs are similar to those in cGVHD patients who have not received MSCs treatment [35]. The correlation between the clinical application of MSC and tumor recurrence and infection requires more high-quality, large-sample clinical trials to verify because the included literature and patient sample sizes are too small.

**Researches on MSC-derived extracellular vesicles (EVs)**

In recent years, the characteristics of extracellular vesicles (EVs) derived from MSCs have aroused great interest among researchers. Scholars believed that the immunosuppressive function of MSCs was related to its paracrine effects induced by EVs [102–104]. MSC-EVs consists of MSC-derived exosomes and microvesicles, among which the multivesicular body fuses with the cell membrane, exposing contents into the extracellular environment. Afterwards, the small vesicles called exosomes with a diameter of about 40–100 nm are formed. The cell membrane directly buds and detaches, forming the larger vesicles with a diameter of about 50–1000 nm called microvesicles [105]. As Zhang et al. put forward, owing to the effect of MSC exosome, CD4+ T cells were induced by APC-related pathway, elevating the population of CD4+CD25+ T cells or CD4+CD25+Foxp3+ Tregs. Followed by Tregs up-regulation, the immunosuppressive effects of MSC exosome were heightened [106]. According to recent researches, similar tissue repair capabilities as MSCs signal that EVs could be a promising non-cellular approach to tackle GVHD disorders instead of MSCs treatment [107]. Fujii et al. reported that MSC-EVs could prolong the survival of aGVHD in mice and reduce the pathological impairment of target organs, accompanied by the decrease in CD4+ and CD8+ lymphocytes levels. The proportion of CD62L-CD44+/CD62L+ CD44- T lymphocytes down-regulated in the meantime, implying a therapeutic effect MSC-EV exerted by inhibiting the differentiation of T lymphocytes from a naive state to a functional state [108]. Kordelas et al. reported a refractory GVHD case who received MSC-EVs therapy. Clinical symptoms including diarrhea and hormone consumption were significantly alleviated, as well as GVHD symptoms in the skin and oral mucosa. Both in vitro and in vivo experiments revealed the MSC-EV reduction of IL-1β, TNF-α, and IFN-γ released from peripheral blood mononuclear cells, as well as TNF-α and IFN-γ released from NK cells [109]. Further investigations on osteoarthristis patient treatment suggested that EVs transferred mRNAs, lipids, siRNA, proteins, miRNAs, and ribosomal RNAs to adjacent cells or remote cells apparently as primary
mediators of intercellular communications, making EVs an absolutely promising instrument in numerous therapies [110]. Having no self-renewal capability, MSC-EVs is small in size, and can be obtained through immortalized cell lines on a large scale. Side effects associated with MSC can also be avoided. Hence high expectations are held over its being a novel non-cellular control method for GVHD.

**Conclusion**

Recent years, MSCs employed in the prevention and treatment of GVHD after allo-HSCT have generated a wealth of basic and clinical researches. MSCs can achieve immunosuppressive function through cell-to-cell contact and release of immunomodulatory factors. According to the existing research, it is well established that soluble factors, oxygen concentration, distinct Toll-like receptors (TLR) ligands, injection dose of MSCs, immunosuppressant adoption and temperature control are engaged in the therapeutic effect of MSCs, yet further research is required to elucidate the specific mechanism. Most studies revealed that MSCs therapy benefited acute and chronic GVHD, which remains to be verified for a lack of large-scale randomized controlled trial. MSC-EVs, as a non-cellular therapy, can avoid some related side effects of MSC, in light of which, researchers call for additional basic and clinical trials towards its specific efficacy and mechanism of prevention and treatment of GVHD. In general, MSCs are very promising in the prevention and treatment of GVHD, and deserves our further attention and research.

**Abbreviations**

allo-HSCT: Allogeneic hematopoietic stem cell transplantation; GVHD: Graft-versus-host disease; MSCs: Mesenchymal stem cells; EVs: Extracellular vesicles; Th1: T helper cells 1; aGVHD: Acute graft-versus-host disease; Th2: T helper cells 2; APC: Antigens presenting cells; CS A: Cyclosporine A; IL-2: Interleukin 2; IL-6: Interleukin 6; IL-10: Interleukin 10; IFNγ: Interferon gamma; IL-12: Interleukin 12; ICAM: Intercellular adhesion molecule; PDGFR-α: Platelet-derived growth factor receptors-alpha; CXCL8: C–X–C Interleukin 6; PGE2: Prostaglandin E2; VEGF: Vascular endothelial growth factor; ICAM: Intercellular adhesion molecule; PD-L1: Programmed death ligand-1; CXCR1: Chemokine (C–X–C motif) receptor 1; CCR1: Chemokine (C–C motif) receptor 1; PDGFR-α: Platelet-derived growth factor receptors-alpha; CXCL8: C–X–C motif chemokine ligand 8; JAK: Janus kinase; STAT1: Signal transducer and activator of transcription 1; Th1: T helper cells 1; aGVHD: Acute graft-versus-host disease; Th2: T helper cells 2; APC: Antigens presenting cells; CS A: Cyclosporine A; IL-2: Interleukin 2; IL-6: Interleukin 6; IL-10: Interleukin 10; IFNγ: Interferon gamma; IL-12: Interleukin 12; ICAM: Intercellular adhesion molecule; PD-L1: Programmed death ligand-1; CXCR1: Chemokine (C–X–C motif) receptor 1; CCR1: Chemokine (C–C motif) receptor 1; PDGFR-α: Platelet-derived growth factor receptors-alpha; CXCL8: C–X–C motif chemokine ligand 8; JAK: Janus kinase; STAT1: Signal transducer and activator of transcription 1; CR: Clinical remission; VCA M: Vascular cell adhesion molecule-1; HIF: Hypoxia inducible factor; COND1: CyclinD1; TNF: Tumor necrosis factor; TLR: Toll-like receptors; LPS: Lipopolysaccharide; CGP: CNDO: CpG oligodeoxynucleotides; PAMP: Pathogen associated molecular patterns; MMF: Mycophenolate mofetil; COX2/PGE2: Cyclooxygenase 2/Prostaglandin E2; OS: Overall survival; TRM: Transplant related mortality; oGVHD: Ocular GVHD; cGVHD: Chronic graft-versus-host disease; AT-MSCs: Adipose tissue-derived MSCs; NS: Nephrotic syndrome.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

XZ and NJ contributed equally to this study. XZ and NJ conceived the idea. XZ and FW did the literature search. XZ drafted the manuscript. All authors read and approved the final manuscript.

**Funding**

This work was supported by The Natural Science Foundation of Jiangsu Province (BK20150639); Natural Science Foundation of Jiangsu Province for Youth (BK20180372); Jiangsu Provincial Medical Youth Talent (QNRC2016812); Key Medical of Jiangsu Province (ZDXKBX2016020); Six talent peaks project in Jiangsu Province (WSW-033); Innovative and entrepreneurial doctors of Jiangsu province (2018ZXJKQW07).

**Availability of data and materials**

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors report no conflicts of interest in this work.

Received: 16 January 2020 Accepted: 27 March 2020 Published online: 07 April 2020

**References**

1. Gyurkocza B, Rezvani A, Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol. 2010;3(3):285–99.
2. Mateos MK, et al. Transplantation-related mortality following allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review. Pediatr Blood Cancer. 2013;60(9):1520–7.
3. Zeiser R, Blazar BR. Acute graft-versus-host disease—biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167–79. 4. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–70.
5. Nazarov C, et al. Assessment of immunosuppressive activity of human mesenchymal stem cells using murine antigen specific CD4 and CD8 T cells in vitro. Stem Cell Res Ther. 2013;4(12):8.
6. Glucksberg H, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-A-matched sibling donors. Transplantation. 1974;18(4):295–304.
7. Harris AC, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10.
8. Hale G, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 2000;26(1):69–76.
9. Jagasia M, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296–307.
10. Friedenstein AJ, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2(2):83–92.
11. Méndez-Ferrer S, et al. Mesenchymal and hematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466(7308):629–34.
12. Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for cellular therapy position statement. Cytotherapy. 2006;8(4):315–7.
13. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008;2(4):313–9.
14. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499–506.
15. Moradian Tehrani R, et al. Mesenchymal stem cells: a new platform for targeting suicide genes in cancer. J Cell Physiol. 2018;233(5):3831–45.
16. Mohammadi M, et al. Mesenchymal stem cell: a new horizon in cancer gene therapy. Cancer Gene Ther. 2016;23(9):285–6.
17. Mirzaei H, et al. Application of mesenchymal stem cells in melanoma: a potential therapeutic strategy for delivery of targeted agents. Curr Med Chem. 2016;23(5):455–63.
18. Mirzaei H, et al. Therapeutic application of multipotent stem cells. J Cell Physiol. 2018;233(4):2815–23.
19. Goradel NH, et al. Stem cell therapy: a new therapeutic option for cardiovascular diseases. J Cell Biochem. 2018;119(7):99–104.
20. Wolff D, et al. Consensus Conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(1):1–17.
21. Devine SM, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 2003;101(8):3099–3101.
22. González MA, et al. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009;136(3):978–89.
23. Sun L, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009;27(6):1421–2.
24. Khosravi M, et al. Induction of CD4(+)CD25(+)Foxp3(+) regulatory T cells by mesenchymal stem cells is associated with RUNX complex factors. Immunol Res. 2018;66(1):207–18.
25. Liu Q, et al. Human mesenchymal stromal cells enhance the immunomodulatory function of CD8(+)CD28(−) regulatory T cells. Cell Mol Immunol. 2015;12(6):708–18.
26. Chen X, Liu Q, Xiang AP. CD8(+)CD28(−) T cells: not only age-related cells but a subset of regulatory T cells. Cell Mol Immunol. 2018;15(8):734.
27. Mougiakakos D, et al. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood. 2011;117(18):4826–35.
28. Guo H, et al. Mesenchymal stem cells overexpressing interleukin-35 propagate immunosuppressive effects in mice. Scand J Immunol. 2017;86(5):389–95.
29. Wang W, et al. Interleukin-35 gene-modified mesenchymal stem cells protect Concanavalin A-induced fulminant hepatitis by decreasing the interferon gamma level. Hum Gene Ther. 2018;29(2):234–41.
30. Maccario R, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4(+)T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005;90(4):516–25.
31. Di Nicola M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonsecretive mitogenic stimuli. Blood. 2002;99(10):3838–43.
32. Rasmusson I, et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation. 2003;76(8):1208–13.
33. Spaggiari GM, et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2002;99(10):3838–43.
34. Concione A, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367–72.
35. Peng Y, et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD56(+)CD3(−) T cells producing interleukin 10. Leukemia. 2005;29(3):636–46.
36. Franquesa M, et al. Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells. 2015;33(3):880–91.
37. Jiang X-Y, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005;105(10):4120–6.
38. van Hoeven V, et al. Mesenchymal stromal cells stimulate the proliferation and IL-22 production of group 3 innate lymphoid cells. J Immunol. 2018;201(4):1165–73.
39. Bouchaka MB, et al. Human mesenchymal stem cell-educated macrophages are a distinct high IL-6-producing subset that confer protection in graft-versus-host-disease and radiation injury models. Biol Blood Marrow Transplant. 2017;23(6):897–905.
40. Davies LC, et al. Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression. Stem Cells. 2017;35(3):766.
41. Ren G, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2(2):141–50.
42. Hajkova M, et al. Mesenchymal stem cells attenuate the adverse effects of immunosuppressive drugs on distinct T cell subpopulations. Stem Cell Rev. 2017;13(1):104–15.
43. Luz-Crawford P, et al. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS ONE. 2012;7(9):e45272.
44. Chen D, et al. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway. Cell Cycle. 2018;17(7):858–67.
45. Yan ZD, et al. Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism. Exp Cell Res. 2014;324(1):65–74.
46. Gallèu A, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunosuppression. Sci Transl Med. 2017;9(416):7828.
47. Eiseon OL, De Bari C. Homing of mesenchymal stem cells: mechanistic or stochastic? Implications for targeted delivery in arthritis. Rheumatology. 2012;51(2):210–8.
48. Ringe J, et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem. 2007;101(1):135–46.
49. Sordi V, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood. 2005;106(2):419–27.
50. Galipeau J, Servèb L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824–33.
51. Kim DS, et al. Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-γ. EBioMedicine. 2018;26:261–73.
52. Kadile RL, et al. Microenvironmental cues enhance mesenchymal stem cell-mediated immunomodulation and regulatory T-cell expansion. PLoS ONE. 2018;13(3):e0193178.
53. Kim DS, et al. Involvement of TLR3-dependent PGES expression in immunosuppression by human bone marrow mesenchymal stem cells. Stem Cell Rev Rep. 2018;14(2):286–93.
54. Liyi Z, et al. Research progress on immunosuppressive effect and mechanism of mesenchymal stem cells in organ transplantation. Organ Transplant. 2019;10(05):612–6.
55. Tang B, et al. The therapeutic effect of ICAM-1-overexpressing mesenchymal stem cells on acute graft-versus-host disease. Cell Physiol Biochem. 2018;46(6):2624–35.
56. Sala E, et al. Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine. Gastroenterology. 2015;149(1):163–176.e20.
57. Mirzaei H, et al. The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model. Cancer Lett. 2018;419:30–9.
58. Yu Y, et al. Knockdown of MicroRNA Let-7a improves the functionality of bone marrow-derived mesenchymal stem cells in immunotherapy. Mol Ther. 2017;25(2):480–93.
59. Estrada JC, et al. Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis. Cell Death Differ. 2012;19(5):743–55.
60. Kim DS, et al. Application of human mesenchymal stem cells cultured in different oxygen concentrations for treatment of graft-versus-host disease in mice. Biomed Res. 2016;37(5):311–7.
61. Zhu C, et al. Hypoxia-inducible factor-2 alpha promotes the proliferation of human placenta-derived mesenchymal stem cells through the MAPK/ERK signaling pathway. Sci Rep. 2016;6:35489.
62. Lv B, et al. Hypoxia inducible factor 1a promotes survival of mesenchymal stem cells under hypoxia. Am J Trans Res. 2017;9(3):1521–9.
63. Liu C, et al. Endothelial differentiation of bone marrow mesenchymal stem cells applicable to hypoxia and increased migration through Akt and NFκB signals. Stem Cell Res Ther. 2017;8(1):29.
64. Lan Y-W, et al. Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Stem Cell Res Ther. 2015;6(1):97.
65. Jiang GM, et al. Effects of hypoxia on the immunomodulatory properties of human gingiva-derived mesenchymal stem cells. J Dent Res. 2015;94(4):669–77.
66. Xie X, et al. Rat BMSC infusion was unable to ameliorate inflammatory injuries in tissues of mice with LPS-induced endotoxemia. Bio-Med Mater Eng. 2017;28(8):5129–38.
67. Sangiorgi B, et al. DSP30 enhances the immunosuppressive properties of mesenchymal stromal cells and protects their suppressive potential from lipopolysaccharide effects: a potential role of adenosine. Cytotherapy. 2016;18(7):846–59.
68. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17(1):1–14.
69. Bunnell BA, Betancourt AM, Sullivan DE. New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Res Ther. 2010;1(5):34.
70. DelaRosa O, Lombardo E. Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. Mediat Inflamm. 2010;2010:865601.
71. Waterman RS, et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS ONE. 2010;5(4):e10088.
72. English K, Mahon BP. Allogeneic mesenchymal stem cells: agents of immune modulation. J Cell Biochem. 2011;112(8):1963–8.
73. Nemeth K, Mayer B, Mezei E. Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands. J Mol Med. 2010;88(1):5–10.
74. Sangiorgi B, Panepucci RA. Modulation of immunoregulatory properties of mesenchymal stromal cells by toll-like receptors: potential applications on GvHD. Stem Cells Int. 2016;2016:943420.
75. Plock JA, et al. Adipose- and bone marrow-derived mesenchymal stem cells proliferate graft survival in vascularized composite allotransplantation. Transplantation. 2015;99(9):1765–73.
76. Eggenhofer E, et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transplant Immunol. 2011;25(2–3):141–7.
77. Inoue S, et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation. 2006;81(11):1589–95.
78. Hajkova M, et al. A local application of mesenchymal stem cells and cyclosporine A attenuates immune response by a switch in macrophage phenotype: J Tissue Eng Regen Med. 2011;5(1):1456–65.
79. Ge W, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant. 2009;9(8):1760–72.
80. Song Y, et al. Use of FGF506 and bone marrow mesenchymal stem cells for rat hind limb allografts. Neuroal Regen Res. 2012;7(4):2681–8.
81. McClain-Caldwell, et al. Immunogenic potential of human bone marrow mesenchymal stromal cells is enhanced by hyperthermia. Cytotherapy. 2018;20(10):1437–44.
82. Le Blanc K, et al. Treatment of severe acute graft-versus-host disease with third-party haploidentical mesenchymal stem cells. Lancet. 2004;363(9419):1439–41.
83. Kuzitgberg J, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant. 2014;20(2):229–35.
84. Chen X, et al. Efficacy of mesenchymal stem cell therapy for steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. PLoS ONE. 2015;10(8):e0136991.
85. André F, et al. Mesenchymal stem cell treatment for steroid refractory graft-versus-host disease in children: a pilot and first study from Turkey. Stem Cells Int. 2016;2016:1641402.
86. Muroi K, et al. Bone marrow-derived mesenchymal stem cells (UR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 2016;103(2):243–50.
87. Dotoli GM, et al. Mesenchymal stem cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52(6):859–62.
88. Česen Mazić M, et al. Treatment of Severe Steroid-Refractory Acute-Graft-versus-Host Disease With Mesenchymal Stem Cells-Single Center Experience. Frontiers in bioengineering and biotechnology. 2018;6:93.
89. Montani K, et al. Mesenchymal Stem Cell Therapy Overcomes Steroid Resistance in Severe Gastrointestinal Acute Graft-Versus-Host Disease: Case Report. Transplant. 2019;2019:7890673.
90. Fan X, et al. Mesenchymal stromal cell (MSC)-derived combination of CILCS and anti-CCL24 is synergistic and superior to MSC and cyclosporine for the treatment of graft-versus-host disease: Biol Blood Marrow Transplant. 2018;24(10):1971–80.
91. Galipeau J. The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013;15(1):12–8.
92. Martinez-Carrasco R, et al. Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GvHD. Ocular Surf. 2019;17(2):285–94.
93. Salmenniemi U, et al. Good responses but high TRM in adult patients after MSC therapy for GvHD. Bone Marrow Transplant. 2017;52(4):660–8.
94. Jurado M, et al. Adipose-tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: a phase VII study. Cytotherapy. 2017;19(8):927–36.
95. Zhang X, et al. Mesenchymal stem cells may ameliorate nephrotic syndrome post-allogeneic hematopoietic stem cell transplantation-case report. Front Immunol. 2017;8:962.
96. Lim J-Y, et al. Mesenchymal stem cells (MSCs) attenuate cutaneous scleroderma-related graft-versus-host disease (Scl-GvHD) through inhibition of immune cell infiltration in a mouse model. J Invest Dermatol. 2017;137(9):1895–904.
97. Hinden L, et al. Lymphocyte counts may predict a good response to mesenchymal stromal cells therapy in graft versus host disease patients. PLoS ONE. 2019;14(6):e0217572.
98. Galleu A, et al. Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. Br J Haematol. 2019;185(1):89–92.
99. Heydari Z, et al. Tissue engineering in liver regenerative medicine: insights into novel translational technologies. Cells. 2020;9(2):E304.
100. Stoma I, et al. Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications. Ann Hematol. 2018;97(5):885–91.
101. Blennow O, et al. Risk factors for invasive mold infections and implications for choice of prophylaxis after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(9):1684–9.
102. Gao F, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7(1):e2062.
103. Phinney DG, et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuffle microRNAs. Nature Commun. 2015;6:8472.
104. Lou G, et al. Exosomes derived from mR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J Hepato Oncol. 2015;8:122.
105. Rani S, et al. Mesenchymal stem cell-derived extracellular vesicles toward cell-free therapeutic applications. Mol Ther. 2015;23(5):812–23.
106. Zhang B, et al. Mesenchymal stromal cell exosome-enhanced regulatory T-cell production through an antigen-presenting cell-mediated pathway. Cytotherapy. 2018;20(3):667–86.
107. Lai P, et al. Novel insights into MSC-EVs therapy for immune diseases. BioMarker Res. 2019;7:6.
108. Fujii S, et al. Graft-versus-host disease amelioration by human bone marrow mesenchymal stromal/stem cell-derived extracellular vesicles is associated with peripheral preservation of naive T cell populations. Stem Cells. 2018;36(3):434–45.
109. Kordelas L, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014;28(4):970–3.
110. Mianehsaz E, et al. Mesenchymal stem cell-derived exosomes: a new therapeutical approach to osteoarthritis? Stem Cell Res Ther. 2019;10(1):340–340.